AKEBIA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.34 USD | +0.75% |
|
-1.47% | +8.06% |
| 23/04 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
| 16/04 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
| Sales 2024 * | 189M 15.72B | Sales 2025 * | 164M 13.71B | Capitalization | 281M 23.39B |
|---|---|---|---|---|---|
| Net income 2024 * | -70M -5.84B | Net income 2025 * | -116M -9.67B | EV / Sales 2024 * | 1.49 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.71 x |
| P/E ratio 2024 * |
-4.62
x | P/E ratio 2025 * |
-4.67
x | Employees | 167 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Akebia Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | +0.75% | ||
| 1 week | -1.47% | ||
| Current month | -26.78% | ||
| 1 month | -33.00% | ||
| 3 months | -17.28% | ||
| 6 months | +62.86% | ||
| Current year | +8.06% |
1 week
1.29
1.41
1 month
1.292.48
Current year
1.212.48
1 year
0.782.48
3 years
0.244.33
5 years
0.2413.71
10 years
0.2431.00
| Managers | Title | Age | Since |
|---|---|---|---|
John Butler
CEO | Chief Executive Officer | 59 | 01/13/01 |
Tracey Vetterick
ADM | Chief Administrative Officer | - | 01/22/01 |
Michel Dahan
COO | Chief Operating Officer | 45 | 01/13/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Rogers
BRD | Director/Board Member | 64 | 12/18/12 |
Adrian Adams
CHM | Chairman | 73 | 12/18/12 |
| Director/Board Member | 65 | 16/21/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.34 | +0.75% | 2,475,964 |
| 25/24/25 | 1.33 | -2.92% | 2,561,124 |
| 24/24/24 | 1.37 | 0.00% | 1,535,781 |
| 23/24/23 | 1.37 | +0.74% | 2,108,817 |
| 22/24/22 | 1.36 | 0.00% | 2,006,106 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Companyâs portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Calendar
06/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.34
USD
Average target price
5
USD
Spread / Average Target
+273.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.06% | 281M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- AKBA Stock
